Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 1046Thoracic 212Gynecologic 181Gastrointestinal 181Head & Neck 136Genitourinary 130Dermatologic 90Sarcoma 43Other solid neoplasm 29CNS 22Lymphoid 19Other hematologic neoplasm 7Endocrine 7Plasma cell 3NET 2Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 3082Neoplasms, Plasma Cell 614Lymphoma 455Lymphoma, Non-Hodgkin 428Recurrence 371Hodgkin Disease 366Leukemia, Lymphocytic, Chronic, B-Cell 362Precursor Cell Lymphoblastic Leukemia-Lymphoma 340Leukemia, Myeloid, Acute 322Leukemia 321Myelodysplastic Syndromes 287Lymphoma, Mantle-Cell 262Lymphoma, Large B-Cell, Diffuse 259Lymphoma, Follicular 254Lymphoma, B-Cell, Marginal Zone 231Burkitt Lymphoma 227Lymphoma, Large-Cell, Immunoblastic 203Myeloproliferative Disorders 197Immunoglobulin Light-chain Amyloidosis 184Neoplasms 182Hematologic Neoplasms 169Primary Myelofibrosis 167Leukemia, Myeloid, Chronic-Phase 165Leukemia, Myeloid, Accelerated Phase 154Lymphoma, T-Cell, Cutaneous 150Waldenstrom Macroglobulinemia 145Blast Crisis 143Leukemia, Myelomonocytic, Chronic 140Mycosis Fungoides 129Sezary Syndrome 128

Interventions

Cyclophosphamide 2pembrolizumab 1fludarabine 1daratumumab 1Rituximab 1Paclitaxel 1Lenalidomide 1Gemcitabine 1Doxorubicin 1Dexamethasone 1Carboplatin 1Capecitabine 1Calcium Dobesilate 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × Plasma cell × Clear all
NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
90 enrolled
BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Gilead Sciences

Phase 1 Terminated
16 enrolled
BreastGynecologicPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡